Novartis
US $ 34.9 billion
One of the top pharmaceutical companies in Switzerland, Novartis Aram has made a list of the top 10 pharmacies for 2019 The company focuses on various disease fields, including oncology, immunology / dermatology, neuroscience and respiratory. Despite the success of the companies Gleevec, and some top-selling drugs facing generic competition in major markets such as Blood Pressure Drug, Dovan and Exforge, the company's revenue increased by 8.8% compared to the figures of 25 figures. To counter this loss, Novartis spent 18% of their total 2017 revenue researching and developing in 2018. Currently, Novartis' best-selling medicines are for gillenia, multiple sclerosis, and lucentitis, for patients suffering from eye-blind disease.
US $ 34.9 billion
One of the top pharmaceutical companies in Switzerland, Novartis Aram has made a list of the top 10 pharmacies for 2019 The company focuses on various disease fields, including oncology, immunology / dermatology, neuroscience and respiratory. Despite the success of the companies Gleevec, and some top-selling drugs facing generic competition in major markets such as Blood Pressure Drug, Dovan and Exforge, the company's revenue increased by 8.8% compared to the figures of 25 figures. To counter this loss, Novartis spent 18% of their total 2017 revenue researching and developing in 2018. Currently, Novartis' best-selling medicines are for gillenia, multiple sclerosis, and lucentitis, for patients suffering from eye-blind disease.
No comments